Skip to main content
main-content

Supportive care and suvivorship

Journal articles and book chapters

02-08-2017 | Lymphoma | Article

Efficacy of palonosetron to prevent delayed nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing repeated cycles of the CHOP regimen

Saito B, Nakashima H, Abe M et al. Support Care Cancer 2017. doi:10.1007/s00520-017-3845-y

28-07-2017 | Glioblastoma multiforme | Article

Prophylactic anticonvulsants in patients with primary glioblastoma

Addressing the controversial topic of using prophylactic anti-epileptic drugs (AEDs) for glioblastoma, this literature review provides new insight into whether AEDs should be used in this setting.

Wali AR et al. J Neurooncol 2017. doi:10.1007/s11060-017-2584-8

20-07-2017 | Head and neck cancers | Article

Psychosocial Issues in Patients with Head and Neck Cancer: an Updated Review with a Focus on Clinical Interventions

This review summarizes psychosocial factors affecting patients with head and neck cancer, and identifies clinical interventions for prevention, identification and treatment of psychiatric comorbidity.

Smith JD, Shuman AG, Riba MB. Curr Psychiatry Rep 2017. doi:10.1007/s11920-017-0811-9

15-06-2017 | Uterine cancer | Article

Radiation-related toxicities and outcomes in endometrial cancer: are obese women at a disadvantage?

Smits et al report a retrospective cohort study which is one of the first to shed light on how the BMI of women diagnosed with endometrial cancer affects the toxicity of radiotherapy they receive and hence survivor quality of life.

Smits A et al. Int J Clin Oncol 2017; 22: 945. doi:10.1007/s10147-017-1147-5

10-06-2017 | Prostate cancer | Article

Effects of resistance exercise in prostate cancer patients: A meta-analysis

The authors find that resistance exercise is a potent approach in counteracting increase of body fat as well as loss of muscle mass, muscle strength, and physical performance in patients suffering from prostate cancer.

Keilani M, Hasenoehrl T, Baumann L et al. Support Care Cancer 2017;25:2953–2968. doi:10.1007/s00520-017-3771-z

20-05-2017 | Glioblastoma multiforme | Article

End of life care for glioblastoma patients at a large academic cancer center

In this study, the authors retrospectively analyze end-of-life care for glioblastoma patients at an academic center to provide a snapshot of end-of-life care for patients in the US.

Kuchinad KE et al. J Neurooncol 2017; 134: 75–81. doi:10.1007/s11060-017-2487-8

04-05-2017 | Hepatocellular carcinoma | Article

Cirrhosis patients with nonalcoholic steatohepatitis are significantly less likely to receive surveillance for hepatocellular carcinoma

This study finds suboptimal hepatocellular carcinoma (HCC) surveillance rates in patients with cirrhosis: Only 49% received surveillance within 6 months and 78% received HCC surveillance within 1 year.

Tavakoli H, Robinson A, Liu B et al. Dig Dis Sci 2017;62:2174–2181. doi:10.1007/s10620-017-4595-x

21-04-2017 | Nausea and vomiting | Review | Article

Management of chemotherapy-induced nausea and vomiting in pediatric patients

This review provides a summary of the safety and efficacy of currently available antiemetic drugs for the prevention of chemotherapy-induced nausea and vomiting (CINV) in children.

Navari RM. Pediatr Drugs 2017; 19: 213–222. doi: 10.1007/s40272-017-0228-2

13-04-2017 | Lymphoma | Article

Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma

Ribi K, Rondeau S, Hitz F et al. Support Care Cancer 2017. doi:10.1007/s00520-017-3698-4

14-03-2017 | Mesothelioma | Article

Physical function and health-related quality of life in patients undergoing surgical treatment for malignant pleural mesothelioma

Tanaka T et al. Support Care Cancer 2017; 25: 2569–2575. doi:10.1007/s00520-017-3666-z

24-02-2017 | Nausea and vomiting | Review | Article

Concise review of the management of iatrogenic emesis using cannabinoids: Emphasis on nabilone for chemotherapy-induced nausea and vomiting

This paper reviews the clinical evidence for the cannabinoids, with a focus on nabilone, for the prevention of chemotherapy-induced nausea and vomiting.

Pergolizzi Jr JV et al. Cancer Chemother Pharmacol 2017; 79: 467–477. doi: 10.1007/s00280-017-3257-1

17-02-2017 | Bladder cancer | Article

The patients’ experience of a bladder cancer diagnosis: A systematic review of the qualitative evidence

Edmondson AJ, Birtwistle JC, Catto JWF, Twiddy M. J Cancer Surviv 2017;11:453–461. doi:10.1007/s11764-017-0603-6

13-02-2017 | Glioblastoma multiforme | Article

Life beyond a diagnosis of glioblastoma: a systematic review of the literature

This article catalogs the range of issues encountered by long-term survivors of glioblastoma and provides greater insight into the symptom burden and care needs of this small, yet important population.

Gately L et al. J Cancer Surviv 2017; 11: 447–452. doi:10.1007/s11764-017-0602-7

09-02-2017 | Neuroendocrine tumors | Article

Web-based information and support for patients with a newly diagnosed neuroendocrine tumor: a feasibility study

The authors investigated whether the use of a web-based system, involving self-screening, patient education, and self-referral to professional healthcare, is feasible in patients with neuroendocrine tumors.

Bouma G et al. Support Care Cancer 2017; 25: 2075–2083. doi:10.1007/s00520-017-3598-7

06-12-2016 | Neuroendocrine tumors | Article

Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: results from an international Phase III trial

Vinik et al. examined the health-related quality of life (HRQoL) of sunitinib-treated patients with pancreatic neuroendocrine tumors and found that survival increased without adversely affecting HRQoL.

Vinik A et al. Targ Oncol 2016; 11: 815–824. doi:10.1007/s11523-016-0462-5

01-12-2016 | Nausea and vomiting | Book chapter | Article

First-generation 5-HT3 receptor antagonists

This chapter provides an overview of the early development and clinical studies of the serotonin (5-hydroxytryptamine-3) receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting.

Chen R, Deng K, Raftopoulos H. In: Management of Chemotherapy-Induced Nausea and Vomiting. Edited by: Navari R. Springer International Publishing Switzerland 2016. doi: 10.1007/978-3-319-27016-6_3

01-12-2016 | Nausea and vomiting | Book chapter | Article

The role of neurokinin-1 receptor antagonists in CINV

This chapter reviews the place of the neurokinin-1 (NK1) receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting (CINV).

Rapoport BL. In: Management of chemotherapy-induced nausea and vomiting. Edited by Navari R. Adis, Cham, 2016. doi: 10.1007/978-3-319-27016-6_5

01-12-2016 | Nausea and vomiting | Book chapter | Article

The physiology and pharmacology of nausea and vomiting induced by anticancer chemotherapy in humans

This chapter provides a review of the mechanisms of chemotherapy-induced nausea and vomiting.

Andrews PLR, Rudd JA. In: Management of Chemotherapy-Induced Nausea and Vomiting. Edited by Navari RM. Springer International Publishing Switzerland 2016. doi: 10.1007/978-3-319-27016-6

01-12-2016 | Nausea and vomiting | Book chapter | Article

Palonosetron

This chapter provides a detailed review of the place of the 5-hydroxytryptamine receptor antagonist palonosetron in the management of chemotherapy-induced nausea and vomiting.

Schwartzberg L. In: Management of Chemotherapy-Induced Nausea and Vomiting. Edited by: Navari R. Springer International Publishing Switzerland 2016. doi: 10.1007/978-3-319-27016-6_4

24-11-2016 | Nausea and vomiting | Article

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: Results of a randomized, double-blind, phase 3 trial versus oral palonosetron

A phase III study was designed to evaluate the efficacy of oral netupitant/palonosetron (NEPA) compared with palonosetron in prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple chemotherapy cycles. Reported here are the results of a multiple cycle extension for the prevention of CINV in patients receiving anthracycline-cyclophosphamide chemotherapy.

Aapro M et al. Support Care Cancer 2017; 25: 1127–1135. doi: 10.1007/s00520-016-3502-x